Reach Us +1-217-403-9671
Viral Ion Channels In Drug Discovery | 8219
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Viral ion channels in drug discovery

2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

Wolfgang B. Fischer

ScientificTracks Abstracts: JBB

DOI: 10.4172/2153-2435.10000S4

G iven the current uncertain climate of pharmaceutical industry, with FDA approved NCEs continue to stagger, antibacterial discovery faces unprecedented challenges, however, huge opportunities exist because the well recognized medical need for new agents to fi ght MDR bacterial infections, such as conditions caused by MRSA and VRE, and also a strong industrial appeal for incentives to invest in this area with orphan drug status, for instance, be granted to novel therapeutics. Here we use one AstraZeneca discovery program to illustrate the challenges and opportunities. Th e inhibition of essential cell-wall targets, such as Glutamate Racemase (MurI), provides a great opportunity to design the next generation of antibacterials. Th is talk will be focused on the recent eff orts of discovering MurI inhibitors in Gram-positive bacteria and Gram-negative Helicobacter Pylori . Th e entire discovery process from High Th roughput Screening, Lead Identifi cation and Lead Optimization will be presented. Emphasis will be given to the demonstration of the power of HTS to discover allosteric enzyme inhibitors and Structural Activity Relationship development employing Structure-Based Drug Design approach
Dr. Bolin Geng is a Principal Scientist of Infection iMed at AstraZeneca R&D Boston . He received his Ph.D. in organic chemistry from University of Montpellier , France, in 1992. Bolin has been working in pharmaceutical industry over the last 15 years, mostly in antibacterial fi eld. He has over 40 publications, patents and patent applications and has contributed to the developments of several ongoing preclinical and clinical drug candidates